Daily close, T-120 (12/12/24) through T+5. Run-up high $20.25 on 5/23/25, low $11.47 on 4/10/25 (T-120 to T-1). FDA decision 5/29/25. Historical price action, not a forecast.
Positioning before the decision
On May 15, 2025, 14 days before the decision date, at-the-money options priced a move of ±21.5% through Jun 20, 2025 (the first listed expiry after the decision; ATM implied volatility 129%). The stock closed -5.8% at the first close across the decision and -15.6% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Was KHINDIVI (ET-400 ( hydrocortisone bioequivalence)) approved by the FDA?
Yes. The FDA approved the application for KHINDIVI (ET-400 ( hydrocortisone bioequivalence)) on May 29, 2025. The primary source is linked on this page.
What was KHINDIVI (ET-400 ( hydrocortisone bioequivalence)) under FDA review for?
The application covered Oral hydrocortisone. The FDA approved the application on May 29, 2025.
How did ETON stock react to the FDA decision?
On the decision day ETON moved -5.8%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.